Business
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imagin...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute MyocarditisARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients.Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness, and can lead to heart failure or sudden cardiac death.There are no FDA-approved drug therapies indicated for the treatment of acute myocarditis.Topline results are expected within the next two weeks.Toronto, Ontario--(Newsfile Corp. - July 22, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (\"Cardiol\" or the \"Company\"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced database lock for ARCHER, the Company's Phase II multi-national, randomized, double-blind, placebo-controlled trial investigating its lead asset, CardiolRx™, on myocardial recovery in patients with acute myocarditis.\"Database lock marks another important milestone in the ARCHER program, enabling statistical analysis, unblinding, and the reporting of topline results, which are now expected within the next two weeks,\" said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. \"As we advance our lead program—the pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis—we believe results from ARCHER will further guide our broader development strategy in forms of heart disease where fibrosis plays a key role.\"Dr. Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development, added, \"Acute myocarditis remains a serious and underserved cardiovascular condition with no approved pharmacological therapy, underscoring the significance of ARCHER. On behalf of the ARCHER Steering Committee and Cardiol Therapeutics, I would like to thank our clinical investigators and the patients and their families for their essential contributions. We look forward to receiving the results of the statistical...